BRENNEN

Industries / Frontier science / Longevity

Trials

This work tests whether a treatment slows aging in people, or in pet dogs, by comparing a treated group with a group given a placebo or no change.

6

Milestones achieved, from 2015 to 2025.

2

To watch for: announced, not yet confirmed outside.

2

Open deliverables. Nobody has shipped them.

The road

AchievedWatch forOpen

Achieved

  1. 2015

    Two years of eating less

    CALERIE, run by teams at the Pennington Biomedical Research Center, Tufts University, Washington University in St. Louis and Duke University, randomly assigned 218 non-obese adults aged 21 to 51 either to eat 25% fewer calories for two years or to eat as usual. Those told to cut calories achieved an average cut of 11.7% and kept off 10.4% of their weight, and 82% of them finished. Risk factors for heart disease fell more than in the usual-diet group, with no harm to quality of life.

    Lessonvolunteers reached less than half the planned cut, so a trial must measure what people actually do, not what they were asked to do.

    pmc.ncbi.nlm.nih.gov

    Credit

    E. Ravussin, L. M. Redman, W. E. Kraus, S. B. Roberts and the CALERIE Study Group

  2. 2019

    Rapalog trial fails phase 3

    Rapalogs are drugs that act on the same mTOR pathway as rapamycin. In 2014 Novartis reported that everolimus (RAD001) raised older volunteers' response to a flu vaccine by about 20%. resTORbio, a Boston company, then ran PROTECTOR 1, a phase 3 trial (the large final stage before approval) of its TORC1 blocker RTB101 in 1,024 adults aged 65 and over through a cold and flu season. In November 2019 it reported that the drug did not reduce respiratory illness: the odds of illness were 0.44 on placebo and 0.46 on the drug.

    Lessona gain in an immune measure in a small trial did not become fewer infections in a large one.

    ebi.ac.uksec.gov

    Credit

    J. B. Mannick and colleagues at Novartis; resTORbio

  3. 2019

    First senolytic tests in people

    In an open-label pilot, where everyone knows what they are taking, 14 people with idiopathic pulmonary fibrosis, a scarring lung disease tied to senescent cells, took dasatinib plus quercetin intermittently for three weeks. All stayed in the study, and walking and chair-stand tests improved, but lung function did not change; the authors called it "first-in-humans". Later in 2019 a pilot in nine people with diabetic kidney disease found fewer senescent cells in fat and skin 11 days after a three-day course.

    Lessonwithout a placebo group, such pilots show that a treatment is feasible, not that it works.

    pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.gov

    Credit

    J. N. Justice, J. L. Kirkland and colleagues; L. J. Hickson and colleagues

  4. 2020

    Senolytic knee shot fails

    UNITY Biotechnology tested UBX0101, a drug meant to remove senescent cells, as a single injection into the knee in 183 people with painful osteoarthritis. On 17 August 2020 it reported no statistically significant difference from placebo in pain at 12 weeks at any dose, and dropped the drug. Its eye drug UBX1325 then fell short of its primary endpoint in a phase 2b trial; in May 2025 UNITY cut its whole workforce, and on 18 September 2025 its stockholders approved dissolving the company.

    Lessonremoving senescent cells in one joint did not ease pain, and a company founded to treat diseases of aging closed before any of its drugs was approved.

    sec.govsec.govsec.gov

    Credit

    UNITY Biotechnology

  5. 2022

    Pet dogs join aging research

    Dogs share people's homes and get many of the same diseases of age, but live much shorter lives. A 2017 pilot gave rapamycin or placebo to 24 healthy middle-aged pet dogs for 10 weeks and saw no clinical side effects. In 2022 the Dog Aging Project published the design of an open-data study of tens of thousands of companion dogs; on 3 November 2026 its site counted 55,159 dogs, and its Test of Rapamycin in Aging Dogs (TRIAD), a placebo-controlled trial, is funded by a 2024 National Institutes of Health grant.

    pmc.ncbi.nlm.nih.govpmc.ncbi.nlm.nih.govdogagingproject.org

    Credit

    K. E. Creevy, D. E. L. Promislow, M. Kaeberlein and the Dog Aging Project Consortium

  6. 2025

    Rapamycin trial, mostly null

    PEARL was a 48-week trial run remotely by AgelessRx, an online medical service in Ann Arbor, Michigan, in which healthy adults aged 50 to 85 took low weekly doses of rapamycin or a placebo, with neither they nor the researchers knowing which; 114 finished. Visceral fat, the main measure, did not change, while lean mass and reported pain improved in women on the higher dose. Partway through, the team learned that the pharmacy-made (compounded) rapamycin it used could be absorbed less well than the commercial drug, and paused the trial to check.

    Lessona trial has to confirm that its drug reaches the blood at the level intended before it starts.

    pmc.ncbi.nlm.nih.gov

    Credit

    M. Moel, G. Harinath, S. L. Morgan, S. Zalzala and colleagues, AgelessRx

Watch for

  1. A prize for restored function

    The XPRIZE Foundation's US$101 million Healthspan competition named 20 finalist teams on 11 August 2026 and gave 10 of them US$1 million each. From 2026 to 2029 the finalists are to run trials of up to one year in adults aged 50 to 90, aiming to restore muscle, cognitive and immune function by at least 10 years, with a target of 20, and XPRIZE plans to award up to US$81 million in 2030.

    Achieved whenthe competition's judges publish trial results, measured through its shared laboratories, in which a team meets the 10-year threshold on all three functions.

    xprize.org

    Claimed by

    the XPRIZE Foundation and its finalist teams, August 2026

  2. Three approved drugs, one trial

    On 24 February 2026 ARPA-H, the US Advanced Research Projects Agency for Health, said a team at the University of Texas Health Science Center at San Antonio would run a phase 3 "hybrid" trial of three drugs already approved for other uses, an SGLT2 inhibitor (the class canagliflozin belongs to), rapamycin and semaglutide, to "establish a regulatory path" for testing drugs against aging. It is one of seven teams in ARPA-H's PROSPR program, which pays by contract as milestones are met.

    Achieved whenthe trial is registered, completes, and publishes results on a main endpoint agreed in advance with the FDA.

    arpa-h.gov

    Claimed by

    ARPA-H, February 2026

Open

  1. 01

    Aging trials, tabled monthly

    A public table, rebuilt every month from trial registries, of every trial in people that names aging, healthspan or longevity as its target, coded for drug or treatment class, age range, size, length, type of primary endpoint (disease onset, physical function, blood marker or aging clock, or what participants report), status, and whether results have been posted.

    The brief
    Credit · unclaimed
  2. 02

    Placebo drift in older adults

    An open reference table of how placebo groups in published randomized trials of adults aged 60 and over change over 6 to 24 months on the measures aging trials use, such as grip strength, gait speed, the Short Physical Performance Battery and aging clocks, built only from published summary tables, so that a small trial's result can be compared with typical change on placebo.

    The brief
    Credit · unclaimed

Open 01 · the brief

Aging trials, tabled monthly

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

A public table, rebuilt every month from trial registries, of every trial in people that names aging, healthspan or longevity as its target, coded for drug or treatment class, age range, size, length, type of primary endpoint (disease onset, physical function, blood marker or aging clock, or what participants report), status, and whether results have been posted.

Why it is still open

The last systematic review of these registrations, by M. A. Syed and colleagues, covered ClinicalTrials.gov only up to May 2022, found "substantial heterogeneity" in the outcomes used, and called for a shared core set. IQVIA, a clinical research company, counted longevity trials in the WHO and US registries up to 17 December 2025 and reported in April 2026 that 2025 alone held nearly a third of them (53), and that since 2020 more trials measure gait speed, the Short Physical Performance Battery (a set of balance, walking and chair-rise tests) and VO2 max; it published charts, not the list of trials or how each was coded. A 2025 survey of 28 experts led by S. Kritchevsky found agreement that blood markers are unlikely to be accepted as main endpoints, but no public, trial-by-trial table shows what registered trials actually measure. On 19 November 2026 ClinicalTrials.gov returned 24 registered studies pairing aging with rapamycin-type drugs, 25 with metformin and 27 with NAD precursors, and none named "Targeting Aging with Metformin", the TAME trial that NPR reported in 2024 was still waiting for US$45 million to US$70 million in funding.

pmc.ncbi.nlm.nih.goviqvia.compmc.ncbi.nlm.nih.govwamc.org

Built with what exists

The ClinicalTrials.gov API (version 2), the EU's Clinical Trials Information System public search, the WHO International Clinical Trials Registry Platform, a language model to draft the codes, and two people to check a share of them.

  1. First step

    Pull every ClinicalTrials.gov record that pairs aging terms with rapamycin, metformin, senolytics or NAD precursors, and hand-code the first 50 to fix the codebook.

  2. Done looks like

    At least 200 trials coded, 20% of them coded twice by different people with at least 95% agreement, refreshed monthly for six months, and published as an open file with a short monthly summary.

Open 02 · the brief

Placebo drift in older adults

Credit · unclaimed

The first to publish is credited on this line, and the deliverable moves from Open to Achieved.

What to build

An open reference table of how placebo groups in published randomized trials of adults aged 60 and over change over 6 to 24 months on the measures aging trials use, such as grip strength, gait speed, the Short Physical Performance Battery and aging clocks, built only from published summary tables, so that a small trial's result can be compared with typical change on placebo.

Why it is still open

XPRIZE Healthspan will judge teams on restoring muscle, cognitive and immune function within a year, and the 2025 expert survey named mobility as a likely part of a combined endpoint, yet a Europe PMC search of titles on 19 November 2026 found no pooled table of placebo-group change on these measures; published meta-analyses compare treated and control groups rather than reporting how much control groups themselves move.

xprize.orgpmc.ncbi.nlm.nih.gov

Built with what exists

Results tables posted on ClinicalTrials.gov, open-access papers through the Europe PMC API, a language model to pull numbers from tables, and two people checking each row against the source.

  1. First step

    Pull posted results for 20 completed placebo-controlled trials in adults aged 65 and over that report gait speed, and enter the placebo-group change by hand.

  2. Done looks like

    At least 100 placebo groups covering at least three measures, each row linked to its source, with change per year and its spread reported by measure and age band, and 20% of rows checked twice.